Abstract
The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin’s lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5–53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1.36, 1.24, 1.03, 0.55 μmol/l respectively, p<0.0001; SDMA: 0.86, 0.76, 0.71, 0.52 μmol/l respectively, p<0.0001). High ADMA and SDMA were associated with increased risk for all-cause mortality in CLL group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58–5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91–11.58, p = 0.001). Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients.
Highlights
Dimethylarginines, asymmetric (ADMA) and symmetric (SDMA), are the methyl derivates of L-arginine, present in human bloodat micromolar levels
High ADMA and SDMA were associated with increased risk for all-cause mortality in chronic lymphocytic leukemia (CLL) group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58–5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91–11.58, p = 0.001)
Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients
Summary
Dimethylarginines, asymmetric (ADMA) and symmetric (SDMA), are the methyl derivates of L-arginine, present in human bloodat micromolar levels. They are the result of degradation of methylated proteins during hydrolytic protein turnover [1]. ADMA inhibits nitric oxide (NO) synthesisvia competitive inhibition of nitric-oxide synthase (NOS) [1,2]. SDMA does not interfere with NOS activity directly but may still have inhibitory effect on NO synthesis by suppressing cellular uptake of its precursor, L-arginine [3,4] and by inhibition of renal tubular absorption of L-arginine [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
